A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma
Top Cited Papers
- 1 July 2020
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Surgical Pathology
- Vol. 44 (7) , 922-933
Abstract
Synovial sarcoma (SS), an aggressive soft tissue sarcoma with a predilection for the extremities of young adults, harbors the pathognomonic t(X;18)(p11;q11) translocation, resulting in SS18-SSX rearrangements. SS includes monophasic, biphasic, and poorly differentiated variants, which show considerable histologic overlap with a range of other tumor types, making the diagnosis challenging on limited biopsies. Immunohistochemistry (IHC) is routinely used in the differential diagnosis; however, presently available markers lack specificity. Thus, cytogenetic or molecular genetic techniques are often employed to confirm the diagnosis. Here, we report the development and characterization of 2 novel antibodies: an SS18-SSX fusion-specific antibody (E9X9V, designed to the breakpoint) as well as an SSX-specific antibody (E5A2C, designed to the SSX C-terminus). We validated the selectivity and specificity of the antibodies using immunoblotting, immunoprecipitation, and chromatin immunoprecipitation followed by next-generation sequencing in SS cell lines and demonstrated that both antibodies capture SS18-SSX on chromatin at established target sites (eg, TLE1 and BCL2) genome-wide. Using IHC in whole sections from 400 tumors including 100 genetically confirmed cases of SS and 300 histologic mimics, the SS18-SSX fusion-specific antibody revealed strong diffuse nuclear staining in 95 of 100 (95%) SS cases, whereas none of the 300 control tumors showed any staining. The SSX antibody showed strong diffuse nuclear staining in all 100 (100%) SS cases; 13 (4%) of the 300 other tumors were also positive, 5 of which displayed >50% nuclear staining. In summary, a novel SS18-SSX fusion-specific antibody is highly sensitive (95%) and specific (100%) for SS, and an antibody to the SSX C-terminus is also highly sensitive (100%), but slightly less specific (96%). IHC using the SS18-SSX antibody could replace molecular genetic or cytogenetic testing in most cases, and these reagents together will also provide the research community with valuable tools for further biochemical and genomic interrogation of the SS18-SSX fusion protein.Keywords
This publication has 28 references indexed in Scilit:
- Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimicsLaboratory Investigation, 2014
- Reversible Disruption of mSWI/SNF (BAF) Complexes by the SS18-SSX Oncogenic Fusion in Synovial SarcomaCell, 2013
- Immunohistochemical Staining for TLE1 Distinguishes Synovial Sarcoma From Histologic MimicsAmerican Journal of Clinical Pathology, 2011
- MUC4 Is a Highly Sensitive and Specific Marker for Low-grade Fibromyxoid SarcomaAmerican Journal of Surgical Pathology, 2011
- TLE1 expression in malignant mesotheliomaVirchows Archiv, 2010
- Reduced expression of SMARCB1/INI1 protein in synovial sarcomaLaboratory Investigation, 2010
- TLE1 expression is not specific for synovial sarcoma: a whole section study of 163 soft tissue and bone neoplasmsLaboratory Investigation, 2009
- CDK8 is a colorectal cancer oncogene that regulates β-catenin activityNature, 2008
- Detection of SS18-SSX fusion transcripts in formalin-fixed paraffin-embedded neoplasms: analysis of conventional RT-PCR, qRT-PCR and dual color FISH as diagnostic tools for synovial sarcomaLaboratory Investigation, 2007
- Cluster analysis of immunohistochemical profiles in synovial sarcoma, malignant peripheral nerve sheath tumor, and Ewing sarcomaLaboratory Investigation, 2006